NRXP Stock News: NRx Pharmaceuticals

NRXP

NRX PHARMACEUTICALS (NRXP) Says FDA Downgraded Ketamine Filing Amendment

The FDA reclassified an amendment to NRx's generic application for preservative-free IV ketamine as minor, setting a GDUFA goal date of November 10, 2026.

NRx is seeking approval for a preservative-free intravenous ketamine product.

NRXP

FDA Reclassifies NRX PHARMACEUTICALS (NRXP) Ketamine Filing to Minor Amendment

NRx says the FDA downgraded an ANDA amendment for preservative-free ketamine from major to minor and set a new GDUFA goal date of November 10, 2026.